Sudeep Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 21, 2026.
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudeep Pharma Limited reported strong FY2026 results with consolidated revenue from operations growing 28% to Rs. 64,225.80 Lakhs (vs Rs. 50,199.92 Lakhs last year). Consolidated Profit After Tax rose 25.6% to Rs. 17,428.47 Lakhs compared to Rs. 13,872.92 Lakhs in FY2025. Standalone PAT stood at Rs. 10,758.07 Lakhs, up 12.4% YoY. The Board recommended a Final Dividend of Rs. 1.50 per equity share (150%) subject to shareholder approval. The company listed on NSE and BSE in November 2025 via IPO, raising net proceeds of Rs. 8,833.59 Lakhs. Additionally, the company acquired 85% stake in Nutrition Supplier & Services (Ireland) Limited for Rs. 12,857.63 Lakhs during the year. Statutory auditors BSR and Co issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
The company demonstrated robust growth with revenue and PAT both growing over 25% year-on-year, indicating strong operational performance. The clean audit opinion and dividend declaration are positive signals for investors. However, the significant increase in trade receivables (Rs. 22,754.43 Lakhs vs Rs. 18,535.48 Lakhs) and inventory buildup warrant monitoring.